$XBI $116.69 +1.43%
Covid Updates
$AZN +0.7% Evusheld (formerly AZD7442) long-acting antibody combination authorised for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19 source
$CYDY +1.0% CytoDyn’s CRO in Brazil Met with ANVISA to Modify CD16 Trial for Critically Ill COVID-19 Patients to Expedite Interim Analysis After 51 Patients, Potentially in 1Q2022. source
$BNTX +3.6% BioNTech to Hold Digital Press Conference to Provide an Update on Omicron Variant. source
$VALN +8.9% Valneva Signs Advance Purchase Agreement with Bahrain for Inactivated COVID-19 Vaccine VLA2001. source
Pipeline Updates
$RDUS -44.3% Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021. source
$RDUS -44.3% Radius Announces Results from the wearABLe Trial Evaluating Abaloparatide Transdermal System in Postmenopausal Women with Osteoporosis. source
$CKPT +5.5% Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer. source
$SUPN 0.0% Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device. source
$CLRB +9.6% Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Exposition. source
$CLDX +2.5% Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis. source
$IMAB +4.2% I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer's Disease. source
$OPK +3.1% OPKO Health Receives U.S. FDA Approval for the 4Kscore® Test. source
$VERU +6.3% Veru Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6 Inhibitor Against Palbociclib Resistant Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Sy. OPKO Health Receives U.S. FDA Approval for the 4Kscore® Test. source
$IGMS +0.9% IGM Biosciences to Collaborate on the Study of IgM and IgA Antibodies for the Prevention of Malaria. source
$NUVB +0.2% Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Advanced Breast Cancer. source
$PASG +2.5% Passage Bio Announces Pipeline Expansion and Clinical Program Update. source
$SAGE +1.3% Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress. source
$AFMD +5.9% Affimed Initiates Patient Recruitment for a Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Roche’s Anti-PD-L1 Checkpoint Inhibitor Atezolizumab. source
$EYPT +3.5% EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce Expanded U.S. Commercial Alliance for DEXYCU®. source
$NBIX +2.4% Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease. source
Business Updates
$RLMD +1.4% Relmada Therapeutics Announces Proposed Public Offering of Common Stock source
$CYAD +13.2% Celyad Oncology Announces Closing of $32.5 Million Private Placement with
Fortress Investment Group Affiliate source
Posted by FS/JM
Comments